References
1. Holmes, L.B., Human teratogens: update 2010. Birth Defects Res A Clin Mol Teratol, 2011. 91 (1): p. 1-7.
2. Twining’s Textbook of Fetal Abnormalities , ed. A.M. Coady and S. Bower. 2014: Elsevier Ltd. 632.
3. Schwarz, E.B., et al., Clinical decision support to promote safe prescribing to women of reproductive age: a cluster-randomized trial. J Gen Intern Med, 2012. 27 (7): p. 831-8.
4. Honein, M.A., C.A. Moore, and J.D. Erickson, Can We Ensure the Safe Use of Known Human Teratogens? Drug Safety, 2004. 27 (14): p. 1069-1080.
5. Addis, A., S. Sharabi, and M. Bonati, Risk Classification Systems for Drug Use During Pregnancy. Drug Safety, 2000.23 (3): p. 245-253.
6. Law, R., et al., FDA pregnancy risk categories and the <em>CPS</em&gt. Canadian Family Physician, 2010.56 (3): p. 239.
7. Services, U.S.D.o.H.a.H. FDA Pregnancy Categories . [date accessed 20/12/2019]; Available from: https://chemm.nlm.nih.gov/pregnancycategories.htm.
8. Mayall, S.J. and A.K. Banerjee, Therapeutic Risk Management of Medicines . 2014. 448.
9. Administration, F.a.D. Approved Risk Evaluation and Mitigation Strategies (REMS) . [date accessed 05/06/2019]; Available from: https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm.
10. Bwire, R., J. Freeman, and F. Houn, Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opin Drug Saf, 2011. 10 (1): p. 3-8.
11. Society, R.P., Medicines Optimisation: Helping patients to make the most of medicines . 2013.
12. Cutler, S., et al., What does medicines optimisation mean for pharmacy professionals? Pharmaceutical Journal, 2011.287 (7680): p. 606-607.
13. Widnes, S.F. and J. Schjott, Risk perception regarding drug use in pregnancy. Am J Obstet Gynecol, 2017. 216 (4): p. 375-378.
14. Collins, J. and D. Bonneh-Barkay, Considerations for Successful Risk-Minimisation Strategies in the EU. Pharmaceutical Medicine, 2016. 30 (5): p. 257-261.
15. Gils, C., et al., Perception of drug teratogenicity among general practitioners and specialists in obstetrics/gynecology: a regional and national questionnaire-based survey. BMC Pregnancy Childbirth, 2016. 16 : p. 226.
16. Sanz, E., T. Gomez-Lopez, and M.J. Martinez-Quintas,Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol, 2001. 95 (1): p. 127-31.
17. Schwarz, E.B., et al., Prescription of teratogenic medications in United States ambulatory practices. Am J Med, 2005.118 (11): p. 1240-9.
18. Brandenburg, N.A., et al., Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention. Drug Saf, 2017.40 (4): p. 333-341.
19. Hayward, K., et al., Reliable Pregnancy Testing Before Intravenous Cyclophosphamide: A Quality Improvement Study. Pediatrics, 2016. 138 (6).
20. Leverenz, D.L., et al., Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol, 2019. 38 (4): p. 1207-1212.
21. Paton, C., et al., A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age. BMJ Open, 2018. 8 (4): p. e020450.
22. Uuskula, A., et al., Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012-2016. Drugs Real World Outcomes, 2018. 5 (2): p. 129-136.
23. Ceulemans, M., et al., Women’s Beliefs About Medicines and Adherence to Pharmacotherapy in Pregnancy: Opportunities for Community Pharmacists. Curr Pharm Des, 2019. 25 (5): p. 469-482.
24. Petersen, I., et al., Women's perception of risks of adverse fetal pregnancy outcomes: a large-scale multinational survey.BMJ Open, 2015. 5 (6): p. e007390.
25. Shrouk, W., D. Steinke, and S. Willis, Risk management of teratogenic medicines: a systematic review. PROSPERO 2019 CRD42019142944. [date accessed 27/04/2020] Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019142944
26. Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 2009.6 (7): p. e1000097.
27. Dabrowska, A., FDA Risk Evaluation and Mitigation Strategies (REMS): Description and Effect on Generic Drug Development . 2018.
28. Arnold, N. FDA In Brief: FDA affirms its commitment to efficient adoption of Risk Evaluation and Mitigation Strategy plans and to making sure they do not impede generic drug development . 2019 [date accessed 15/10/2019]; Available from: https://www.fda.gov/news-events/fda-brief/fda-brief-fda-affirms-its-commitment-efficient-adoption-risk-evaluation-and-mitigation-strategy.
29. Hawker, S., et al., Appraising the evidence: reviewing disparate data systematically. Qual Health Res, 2002. 12 (9): p. 1284-99.
30. Mitchell, A.A., C.M. Van Bennekom, and C. Louik, A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin. New England Journal of Medicine, 1995. 333 (2): p. 101-106.
31. Cheetham, T.C., et al., A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study.J Am Acad Dermatol, 2006. 55 (3): p. 442-8.
32. Steinkellner, A., W. Chen, and S.E. Denison, Adherence to oral contraception in women on Category X medications. Am J Med, 2010.123 (10): p. 929-934.e1.
33. Rao, R.S., et al., Comparison of alternative survey methods for sensitive self-reported behaviours in a follow-up study of isotretinoin. J Epidemiol Biostat, 2000. 5 (2): p. 133-6.
34. Pinheiro, S.P., et al., Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.Pharmacoepidemiol Drug Saf, 2013. 22 (12): p. 1251-7.
35. Yazdany, J., et al., Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?Arthritis Care Res (Hoboken), 2011. 63 (3): p. 358-65.
36. Force, R.W., et al., Contraceptive methods and informed consent among women receiving medications with potential for adverse fetal effects: a Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) region study. J Am Board Fam Med, 2012. 25 (5): p. 661-8.
37. Stancil, S.L., et al., Contraceptive Provision to Adolescent Females Prescribed Teratogenic Medications. Pediatrics, 2016.137 (1).
38. Schwarz, E.B., et al., Counseling about medication-induced birth defects with clinical decision support in primary care. J Womens Health (Larchmt), 2013. 22 (10): p. 817-24.
39. Schwarz, E.B., et al., Counseling of female veterans about risks of medication-induced birth defects. J Gen Intern Med, 2013.28 Suppl 2 : p. S598-603.
40. Schwarz, E.B., et al., Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Annals of internal medicine, 2007.147 (6): p. 370-376.
41. Gotlib, D., et al., Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review. The Journal of clinical psychiatry, 2016. 77 (4): p. 527-534.
42. Landis, E.T., et al., Isotretinoin and oral contraceptive use in female acne patients varies by physician specialty: analysis of data from the National Ambulatory Medical Care Survey. J Dermatolog Treat, 2012. 23 (4): p. 272-7.
43. Fritsche, M.D., A.Z. Ables, and H. Bendyk, Opportunities missed: improving the rate of contraceptive counseling or provision when prescribing reproductive-aged women potentially teratogenic medications in a family medicine resident clinic. Contraception, 2011.84 (4): p. 372-6.
44. Schwarz, E.B., et al., Provision of potentially teratogenic medications to female veterans of childbearing age. Med Care, 2010.48 (9): p. 834-42.
45. Castaneda, C.P., et al., RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide.Drug Saf, 2008. 31 (9): p. 743-52.
46. Bhakta, J., J. Bainbridge, and L. Borgelt, Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy. Epilepsy Behav, 2015. 52 (Pt A): p. 212-7.
47. Brinker, A., C. Kornegay, and P. Nourjah, Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Arch Dermatol, 2005. 141 (5): p. 563-9.
48. Goyal, M.K., et al., Underuse of pregnancy testing for women prescribed teratogenic medications in the emergency department. Acad Emerg Med, 2015. 22 (2): p. 192-6.
49. Mody, S.K., et al., Using the electronic medical record to assess contraception usage among women taking category D or X medications. Birth Defects Res A Clin Mol Teratol, 2015.103 (10): p. 887-91.
50. Mody, S.K., et al., Using the electronic medical record to refer women taking category D or X medications for teratogen and contraceptive counseling. Birth Defects Res A Clin Mol Teratol, 2015.103 (7): p. 644-7.
51. DiPietro Mager, N., C. Mills, and A. Snelling, Utility of reproductive life plans in identification of potentially teratogenic medication use: A pilot study. Birth, 2018. 45 (1): p. 50-54.
52. Ferguson, S., et al., Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication. Lupus, 2016.25 (1): p. 12-7.
53. Werner, C.A., et al., Women’s experiences with isotretinoin risk reduction counseling. JAMA Dermatol, 2014. 150 (4): p. 366-71.
54. Wieck, A., et al., A survey of antiepileptic prescribing to women of childbearing potential in psychiatry. Arch Womens Ment Health, 2007. 10 (2): p. 83-5.
55. Valle, J., et al., Contraceptive use by women receiving chemotherapy for breast cancer. The Breast, 1998. 7 (3): p. 143-149.
56. Bell, G.S., et al., Information recalled by women taking anti-epileptic drugs for epilepsy: a questionnaire study. Epilepsy Res, 2002. 52 (2): p. 139-46.
57. James, L., et al., Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists. J Psychopharmacol, 2007. 21 (8): p. 815-9.
58. Langan, J., A. Perry, and M. Oto, Teratogenic risk and contraceptive counselling in psychiatric practice: analysis of anticonvulsant therapy. BMC Psychiatry, 2013. 13 : p. 234.
59. Chave, T.A., A.Y. Finlay, and A.G. Knight, Thalidomide usage in Wales: the need to follow guidelines. Br J Dermatol, 2001.144 (2): p. 310-5.
60. Martin, U., et al., Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther, 2008.33 (5): p. 507-11.
61. Atturu, H. and A. Odelola, Valproate Prescribing in Women of Childbearing Age: An Audit of Clinical Practice. Advances in Psychiatry, 2015. 2015 : p. 6.
62. Shilalukey, K., et al., Counseling sexually active teenagers treated with potential human teratogens. J Adolesc Health, 1997.21 (3): p. 143-6.
63. Hogan, D.J., L.M. Strand, and P.R. Lane, Isotretinoin therapy for acne: a population-based study. Cmaj, 1988. 138 (1): p. 47-50.
64. Boucher, N. and L. Beaulac-Baillargeon, Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations. Canadian family physician Medecin de famille canadien, 2006. 52 (3): p. 338-339.
65. Ruiter, R., et al., Concomitant use of contraceptives and potentially teratogenic medicinal products–results from a study using pharmacy dispensing data in the Netherlands. Reprod Sci, 2012.19 (9): p. 987-94.
66. Teichert, M., et al., Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data. Drug Saf, 2010. 33 (4): p. 315-26.
67. Crijns, H.J., et al., Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study. Pharmacoepidemiol Drug Saf, 2012.21 (10): p. 1060-6.
68. Bosak, M., K. Cyranka, and A. Slowik, Hormonal contraception in patients with epilepsy. Ginekol Pol, 2019. 90 (2): p. 61-65.
69. Banas, T., et al., Use of contraception by women treated with leflunomide due to rheumatic arthritis. J Obstet Gynaecol, 2014.34 (1): p. 60-4.
70. Mulryan, D., et al., Awareness and documentation of the teratogenic effects of valproate among women of child-bearing potential. BJPsych Bull, 2018. 42 (6): p. 233-237.
71. Lelubre, M., et al., Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium. Pharmacoepidemiol Drug Saf, 2018.27 (6): p. 668-673.
72. Raguideau, F., et al., Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin. Pharmacoepidemiol Drug Saf, 2015. 24 (5): p. 526-33.
73. Entezari-Maleki, T., et al., Evaluation and monitoring of isotretinoin use in Iran. Arch Iran Med, 2012. 15 (7): p. 409-12.
74. Ozyurt, S. and A.F. Kaptanoglu, Systemic Isotretinoin Treatment and Pregnancy: A Longitudinal Cohort Study from Turkey. The Eurasian journal of medicine, 2015. 47 (3): p. 179-183.
75. Tsur, L., E. Kozer, and M. Berkovitch, The effect of drug consultation center guidance on contraceptive use among women using isotretinoin: a randomized, controlled study. J Womens Health (Larchmt), 2008. 17 (4): p. 579-84.
76. Chang, A.Y., et al., Motivations of women in Uganda living with rheumatic heart disease: A mixed methods study of experiences in stigma, childbearing, anticoagulation, and contraception. PLoS One, 2018. 13 (3): p. e0194030.
77. Algoblan, S., et al., Women's experiences regarding isotretinoin risk reduction counseling in Riyadh. Journal of Dermatology and Dermatologic Surgery, 2019. 23 (1): p. 13-15.
78. Schwarz, E.B., et al., Promoting safe prescribing in primary care with a contraceptive vital sign: a cluster-randomized controlled trial. Ann Fam Med, 2012. 10 (6): p. 516-22.
79. Lupattelli, A., et al., Health literacy and its association with perception of teratogenic risks and health behavior during pregnancy. Patient Educ Couns, 2014. 96 (2): p. 171-8.
80. Nordeng, H., E. Ystrom, and A. Einarson, Perception of risk regarding the use of medications and other exposures during pregnancy.Eur J Clin Pharmacol, 2010. 66 (2): p. 207-14.
81. Damase-Michel, C., et al., Perception of teratogenic and foetotoxic risk by health professionals: a survey in Midi-Pyrenees area. Pharmacy practice, 2008. 6 (1): p. 15-19.
82. Pons Eda, S., S. Pizzol Tda, and D.R. Knauth, Perceptions by pregnant and childbearing-age women in southern Brazil towards teratogenic risk from medicines and radiotherapy. Cad Saude Publica, 2014. 30 (9): p. 1965-76.
83. Leiderman, D.B., Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Drug Alcohol Depend, 2009. 105 Suppl 1 : p. S9-S13.
84. Crijns, H.J., et al., Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol, 2011. 164 (2): p. 238-44.
85. Bérard, A., et al., Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. British Journal of Clinical Pharmacology, 2007. 63 (2): p. 196-205.
86. Althubaiti, A., Information bias in health research: definition, pitfalls, and adjustment methods. Journal of multidisciplinary healthcare, 2016. 9 : p. 211-217.
87. Schmier, J.K. and M.T. Halpern, Patient recall and recall bias of health state and health status. Expert Rev Pharmacoecon Outcomes Res, 2004. 4 (2): p. 159-63.
88. Social Desirability Bias , in Wiley International Encyclopedia of Marketing .
89. Herrett, E., et al., Data Resource Profile: Clinical Practice Research Datalink (CPRD). International Journal of Epidemiology, 2015.44 (3): p. 827-836.
90. Zozus, M.N., et al., Factors Affecting Accuracy of Data Abstracted from Medical Records. PLOS ONE, 2015. 10 (10): p. e0138649.
91. Freeman, J., et al., Teratogenic Drugs and Risk Management: An Implementation Assessment. Ther Innov Regul Sci, 2014. 48 (4): p. 420-427.
92. Shorten, A. and J. Smith, Mixed methods research: expanding the evidence base. Evidence Based Nursing, 2017. 20 (3): p. 74-75.
93. Tisnado, D.M., et al., What Is the Concordance between the Medical Record and Patient Self-Report as Data Sources for Ambulatory Care? Medical Care, 2006. 44 (2): p. 132-140.
94. Peters, E., et al., Numeracy Skill And The Communication, Comprehension, And Use Of Risk-Benefit Information. Health Affairs, 2007. 26 (3): p. 741-748.
95. Rothman, R.L., et al., Perspective: the role of numeracy in health care. Journal of health communication, 2008. 13 (6): p. 583-595.
96. Pons, E.d.S., et al., Analysis of agreement between Visual Analogue Scales (VAS) and numerical questions to assess perception of teratogenic risks in treatment with drugs and radiotherapy in women.Revista Brasileira de Saúde Materno Infantil, 2014. 14 : p. 393-399.
97. Harland, N.J., M.J. Dawkin, and D. Martin, Relative utility of a visual analogue scale vs a six-point Likert scale in the measurement of global subject outcome in patients with low back pain receiving physiotherapy. Physiotherapy, 2015. 101 (1): p. 50-54.
98. Twigg, M.J., A. Lupattelli, and H. Nordeng, Women’s beliefs about medication use during their pregnancy: a UK perspective.International Journal of Clinical Pharmacy, 2016. 38 (4): p. 968-976.
99. Polifka, J.E., E.M. Faustman, and N. Neil, Weighing the risks and the benefits: A call for the empirical assessment of perceived teratogenic risk. Reproductive Toxicology, 1997. 11 (4): p. 633-640.
100. Lennon, S.L., Risk perception in pregnancy: a concept analysis. Journal of Advanced Nursing, 2016. 72 (9): p. 2016-2029.
101. Widnes, S.F., et al., Teratogenic risk perception and confidence in use of medicines in pairs of pregnant women and general practitioners based on patient information leaflets. Drug Saf, 2013.36 (6): p. 481-9.
102. Schwarz, E.B., et al., Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Res A Clin Mol Teratol, 2009. 85 (10): p. 858-63.
Table 1. Specific risk minimisation measures reported in the included papers.